SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, announces that President and CEO Michael Nall is scheduled to present a corporate overview at the LD Micro Invitational Conference on June 1, 2015, at 1:00 p.m. Pacific time (4:00 p.m. Eastern time). The conference is being held at the Luxe Sunset Bel Air hotel in Los Angeles.
A live webcast of the presentation will be available on the investor relations page of the Company’s corporate website at ir.biocept.com. A replay of the presentation will be available for 90 days.
About Biocept, Inc.
Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept’s technology platform captures and analyzes circulating tumor DNA, both in CTCs and in plasma (ctDNA). Biocept currently offers OncoCEE-GA™ for gastric cancer, OncoCEE-BR™ for breast cancer and OncoCEE-LU™ for non-small cell lung cancer, and plans to introduce CLIA-validated tests for colorectal, prostate and other solid tumors in the near term.
